LPT 99

Drug Profile

LPT 99

Alternative Names: LPT99

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Loop Therapeutics
  • Developer Spiral Therapeutics
  • Class Small molecules
  • Mechanism of Action Apoptosis inhibitors; Apoptotic protease activating factor 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hearing loss

Most Recent Events

  • 26 Sep 2017 Spiral Therapeutics receives positive feedback from the US FDA for its pre-IND submission for LPT 99
  • 26 Sep 2017 Spiral Therapeutics plans a phase I trial for Hearing loss in USA in early 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top